FDA Approves First Immunotherapy for Initial Treatment of Gastric Cancer

Home / Articles / External / Government

https://www.nih.gov/news-events/nih-research-matters/predicting-response-immunotherapy
3d render of immune system T cells attacking cancer cells

April 19, 2021 | Originally published by U.S. Food and Drug Administration (FDA) on April 16, 2021

Today, the U.S. Food and Drug Administration approved Opdivo (nivolumab), in combination with certain types of chemotherapy, for the initial treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer and esophageal adenocarcinoma. This is the first FDA-approved immunotherapy for the first-line treatment of gastric cancer.

Focus Areas